

BG SALES-TRADING MORNING DU 22/03/2016

LA SEANCE DE LA VEILLE

INDICES U.S & JAPON				SECTEURS S&P : BEST PERFS			SECTEURS STOXX : BEST PERFS			
Indices	Cloture	Var %	Var 17h30-22H (en %)	S&P	Var %	YTD	STOXX	Var %	YTD	
DJ	17623,9	0,1%	-	PHARMA.	1	-8,6	Chemicals	1,1	-6	
NASDAQ	4808,9	0,3%	-	Consumer Durables	0,9	6,2	Healthcare	0,6	-12,8	
S&P 500	2051,6	0,1%	-	Telecom Op.	0,6	14	Real Estate	0	-2,5	
NIKKEI	17048,6	1,9%	-	IT, SOFTW & Serv.	0,6	0,3	Food & BeV	0	-3,5	
				SECTEURS S&P : WORST PERFS.			SECTEURS STOXX : WORST PERFS			
				S&P	Var %	YTD	STOXX	Var %	YTD	
				Real Estate	-0,7	1,2	Oil & Gas	-1,6	2,2	
				Health Equip.	-0,5	-2,6	Basic Resources	-1,3	11,8	
				Materials	-0,5	3,7	Technology	-0,7	-6,8	
				Oil & Gaz	-0,5	5	Financial Serv.	-0,6	-10,1	

Valeurs les plus traitées hier vs. Moy. 3M

CAC 40			EURO STOXX 50			STOXX 600		
Stocks*	Last	Var%	Stocks*	Last	Var%	Stock*s	Last	Var%
NOKIA OYJ	5,4	-0,3	TELEFONICA SA	10	-0,1	BANKINTER SA	6,4	-0,4
UNIBAIL-RODAMCO	249,5	-0,5	BAYER AG-REG	102,5	3,3	SAINSBURY (J) PLC	276,5	1,2
SAFRAN SA	60,8	-0,1	UNIBAIL-RODAMCO	249,5	-0,5	HOWDEN JOINERY	466,4	-0,1
ARCELORMITTAL	3,9	-4	SAFRAN SA	60,8	-0,1	FREENET AG	26,5	-0,4
KLEPIERRE	41,9	0,5	GENERALI	13,5	-1,2	MONEYSUPERMARKET.	325,4	-0,8

DEFINITION : * compare les capitaux traités sur une valeur la veille rapportés à la moyenne des capitaux traités ces 3 derniers mois sur la valeur.

TAUX U.S

Taux U.S	Valeur	Var%	Yld	Devises	Valeur	Var%	YTD	Mat. Prem	Valeur	Var%	YTD
U.S 2 ANS	99,8	0%	0,9%	€/ \$	1,1241	-0,4%	3%	BRENT	40,6	0,2%	13,6%
U.S 10 ANS	97,4	0%	1,9%	€/ ¥	126,08	-0,2%	3,6%	ONCE OR (\$)	1250,9	0,3%	17,7%

VIX Index	13,8	-1,6%	VSTOXX Index	21,8	5,7%
-----------	------	-------	--------------	------	------

Economic Calendar

JP - industry activity (2.0% A)
 JP - PMI mfg Mar. (49.1A, 50.5E)
 DE - German IFO Business climate Mar.
 DE - IFO expectations Mar. (99.8E)
 GB - CPI Feb. (+0.4%E y/y)
 GB - Core CPI Feb. (1.2%E y/y)
 DE - ZEW Eco Sentiment Mar (5.9 E)
 US - House price index Jan. (0.5% E)

Dividends Calendar ex-date next day

Ex Div today

METSO (MEO1V.HE) 1.05€ (4.74%)

Markets Recap (source Street account)

Asian markets are trading narrowly mixed on Tuesday. It has been a subdued trading session that has lacked any real impetus. Some fatigue may be setting in with recent outperformers like commodity equities among the regional laggards. The Nikkei is back online and gaining amid renewed yen weakness. There have also been more signals from government officials about a possible delay in next year's consumption tax hike. Greater Chinese markets are weaker in early trade. Banks have come into focus amid reports the industry regulator is reportedly lowering their minimum bad debt coverage ratio while urging them limit shareholder payouts in a bid to shore up capital.

US equities finished slightly higher in quiet trading on Monday. Treasuries were weaker with some curve steepening. The dollar was modestly higher with the DXY +0.29%. Gold (0.8%) was lower. Oil was higher; WTI +1.2% and Brent +0.8%.

No clear catalysts resulted in desultory trading during a quiet session. Hawkish fed commentary was in focus. February existing home sales disappointed. M&A activity generated a number of headlines. The ongoing Valeant (VRX) saga also provided numerous headlines.

Sectors were mixed. Telecom +0.57% was the best performer. Materials (0.50%) and energy (0.50%) were the worst performers.

Week ahead: is expected to be quiet with both corporate and economic calendars on the lighter side. New home sales are due on Wednesday, 23-Mar. Flash PMIs are due on Thursday, 24-Mar. Markets will be closed on 25-Mar in observance of Good Friday.

Stocks Factor to watch today :

SWISS WATCH eports fall 3.3% in feb. Y/y in nominal terms

BIOMERIEUX : and Copan announce the first commercial success of their collaboration

MEYER BURGER : FY 2015 EBITDA loss narrows to 55.9mCHF

Rating & TP Changes



SOFTWARE AG : TP raised to 34€ vs. 38, BUY @BRYAN GARNIER



ADOCIA : TP cut to 100€ vs. 113€, BUY @BRYAN GARNIER

LUXOTTICA : TP cut to 63€ vs. 65, BUY @ BRYAN GARNIER

ROCHE : HOLD vs. BUY, TP 262CHF vs. 325 @ HSBC

ASTRAZENECA : TP cut to 4350p vs. 4880, HOLD @HSBC

NOVARTIS : TP cut to 97CHF vs. 102, BUY @HSBC

RANDSTAD : TP cut to 60CHF vs. 102, BUY @ HSBC

ADECCO : TP cut to 80CHF vs. 90, BUY @ HSBC

Bryan Garnier ... Today's comment(s)

Gameloft RATING : BUY Fair Value EUR6.7 (-8%)

FY15 underlying op. profit before SO came to EUR2.1m (vs. our breakeven est. and cons. of EUR1.6m) and net loss to -EUR24.2m (vs. our -EUR22.7m and cons. of -EUR18.2m). We expect the group's op. margin to return to past levels in 2016e (BG. est. 11.5%, cons. of 8.3%). Management has just provided its strategic plan, which will be detailed this afternoon in London. Its 2018 targets are higher by 14% in sales, by 50% in underly. op. profit and by 10% in cumulative FCF compared with our estimates. Regarding the speculation surrounding the stock, we cannot exclude a new increase in the offer price as 1/ the share is trading above Vivendi's last offer and 2/ Gameloft's 2018 targets are promising. As a reminder, we estimate a fair offer in the range EUR7.2/8.4. We maintain our Buy rating. => Positive

Luxottica RATING : BUY Fair Value EUR63 vs. EUR65 (+29%)

After an excellent performance in 2015 (+33%), the share has plummeted 19% YTD, due to 2016-18 targets viewed as cautious by the market and a lack of visibility concerning governance. The share is now trading at a 5% discount in terms of 1-yr forward EV/EBIT relative to the average over 2014-16 (vs. +32% in December) and since we believe that management will provide convincing answers to these two issues, we advise making the most of current prices to strengthen positions. We have made no changes to our 2016-18 estimates but our new EUR63 Fair Value takes account of a slight increase in beta as well as the number of shares. Buy recommendation confirmed.

Software AG RATING : BUY Fair Value EUR38 vs. EUR34 (+15%)

We raise our DCF-derived fair value to EUR38 from EUR34 on an increase to our medium-term adj. EBIT margin assumption (to 35% from 33% = +EUR2/share) and an update to our WCR ests. (+EUR2/share). The meetings held at our TMT conference confirmed that the sales transformation led by Eric Duffaut has started to bear fruit, gradually raising Software AG's stock market status to "growth" from "value". Positive.

Sopra Steria Group	RATING : BUY	Fair Value EUR113 (+9%)
--------------------	--------------	-------------------------

The conference comforts our positive view: 1). The integration of Steria led to faster-than-expected synergies; 2). Free cash flow is improving; 3). The group is growing faster than its market; and 4). The operating margin is catching up with the best European players in IT Services. We consider the 8-9% operating margin target for 2017 is achievable. Positive.

Genmab	RATING : BUY-Top Picks	Fair Value DKK1170 (+43%)
--------	------------------------	---------------------------

Genmab announced that daratumumab (an anti-CD38) will be investigated in early-stage clinical studies (Phase Ib) in combination with Roche's atezolizumab (an anti-PD-L1) in a solid tumor, and multiple myeloma. We see this as 1) a strong validation of the best-in-class status of daratumumab as a treatment for MM... and we think this novel triplet combo could bring the bar even higher, and 2) potentially as another step towards the enlargement of the addressable market with other malignancies (be it prostate cancer or non-hodgkin lymphomas). BUY reiterated with a FV of DK1,170.
